GenoMed in Collaboration to Treat Acute Kidney Failure in Turkish Earthquake Victims
ST. LOUIS, May 2 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri- based medical genomics and Next Generation Disease Management(TM) company, announced today that it is working with Turkish medical authorities caring for victims of yesterday's earthquake in Bingol in eastern Turkey.
The current casualty estimates are 250 dead and 1,000 injured, including 50 who will require kidney dialysis for crush injury syndrome. Crush injury syndrome, a form of rhabdomyolysis, involves muscle breakdown and acute kidney failure. Normally, dialysis is required until kidney function recovers days to weeks later. Some patients may require dialysis indefinitely, taxing the country's ability to provide expensive medical care. Of 12 survivors brought to hospital yesterday, 7 are already on kidney dialysis.
GenoMed has applied for patent protection on the use of an existing drug, aminophylline, to restore kidney function and avoid dialysis in the setting of acute kidney failure. Its treatment has worked in adults and infants in the hospital setting, but this is the first time it will be used for earthquake victims. GenoMed has licensed its treatment to Dr. Mehmet Sukru Sever for use among Bingol earthquake victims. Dr. Sever coordinates kidney dialysis for survivors of the earthquake.
Dr. David Moskowitz, GenoMed's Chairman and CEO, said, "We believe our treatment will work in crush injury, just as it has worked for other causes of acute kidney failure. We have seen restoration of kidney function within hours in the hospital setting. This is significant, since acute kidney failure greatly increases the risk of dying, as well as the cost of hospitalization. If we can restore kidney function rapidly in earthquake victims, they will have a better survival rate, and will be less likely to require long-term dialysis."
Dr. Moskowitz continued, "Given that school-children are still trapped in the rubble, and at increasing risk for crush injury syndrome, it is reassuring to know that our treatment has already been used safely among the most vulnerable children: infants in a Neonatal ICU."
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. The Company has filed world-wide patent applications on its new treatments, and is eager to license them globally. GenoMed's research results are more fully described on its website, www.genomedics.com
For questions, please contact David Moskowitz MD or David Pollack at 314-977-0110, FAX 314-977-0042, email: dwmoskowitz@genomedics.com or dpollack@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: David Moskowitz, MD, e-mail, dwmoskowitz@genomedics.com, or
David Pollack, e-mail, dpollack@genomedics.com, both of GenoMed, Inc.,
+1-314-977-0110, or fax, +1-314-977-0042/
Web site: genomedics.com /
. |
